Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AOC3 | Q16853 | 2/20 | 0.48 |
| ▸ | BRD4 | O60885 | 1/20 | 0.47 |
| ▸ | RAB9A | P51151 | 4/20 | 0.45 |
| ▸ | NPC1 | O15118 | 3/20 | 0.45 |
| ▸ | LOXL2 | Q9Y4K0 | 1/20 | 0.44 |
| ▸ | FLT3 | P36888 | 1/20 | 0.44 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.44 |
| ▸ | AURKA | O14965 | 1/20 | 0.43 |
| ▸ | AURKB | Q96GD4 | 1/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.43 |
| ▸ | MAPT | P10636 | 5/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.43 |
| ▸ | HPGD | P15428 | 3/20 | 0.42 |
| ▸ | DAO | P14920 | 2/20 | 0.42 |
| ▸ | SRD5A2 | P31213 | 1/20 | 0.42 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.42 |
| ▸ | DDO | Q99489 | 1/20 | 0.42 |
| ▸ | CA2 | P00918 | 1/20 | 0.41 |
| ▸ | ESR1 | P03372 | 1/20 | 0.41 |
| ▸ | CASP3 | P42574 | 2/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30559751 | 1.00 | AOC3 (0.48) | AOC3BRD4RAB9ANPC1LOXL2 | |
| SCHEMBL30559750 | 1.00 | AOC3 (0.48) | AOC3BRD4RAB9ANPC1LOXL2 | |
| SCHEMBL15791226 | 0.83 | AOC3 (0.45) | AOC3BRD4RAB9ANPC1LOXL2 | |
| SCHEMBL17546182 | 0.80 | KDM4E (0.46) | AOC3BRD4RAB9ANPC1LOXL2 | |
| SCHEMBL7019205 | 0.79 | AOC3 (0.45) | AOC3BRD4RAB9ANPC1LOXL2 | |
| SCHEMBL19557306 | 0.78 | ALDH1A1 (0.47) | AOC3BRD4RAB9ANPC1LOXL2 | |
| 2-Methylindole SCHEMBL12420 | 0.70 | BRD4 (0.57) | AOC3BRD4RAB9ANPC1LOXL2 | |
| 2-Methylindole SCHEMBL29377448 | 0.70 | BRD4 (0.57) | AOC3BRD4RAB9ANPC1LOXL2 | |
| SCHEMBL1854303 | 0.69 | CYP2A6 (0.58) | AOC3BRD4RAB9ANPC1LOXL2 | |
| SCHEMBL10479143 | 0.69 | AOC3 (0.44) | AOC3BRD4RAB9ANPC1LOXL2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-115417859-B | Synthesis method of rizatriptan benzoate | 陕西师范大学 | 2024-02-02 | — | — | CN | disclosed |
| CN-115417859-A | Synthetic method of rizatriptan benzoate | 陕西师范大学 | 2022-12-02 | — | — | CN | disclosed |
| US-8076365-B2 | Viral polymerase inhibitors | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2011-12-13 | — | — | US | disclosed |
| US-20100168098-A1 | Viral Polymerase Inhibitors | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-07-01 | — | — | US | disclosed |
| EP-1915378-A4 | VIRAL POLYMERASE INHIBITORS | BOEHRINGER INGELHEIM INT (DE) | 2009-07-22 | — | — | EP | disclosed |
| US-20080167476-A1 | Process for the preparation of 2-substituted-7-Boryl indoles and compounds | BOARD OF TRUSTEES OF MICHIGAN STATE UNIVERSITY (US) | 2008-07-10 | — | — | US | disclosed |
| EP-1915378-A1 | VIRAL POLYMERASE INHIBITORS | Boehringer Ingelheim International GmbH (DE) | 2008-04-30 | — | — | EP | disclosed |
| US-7183252-B2 | Indole peptidomimetics as thrombin receptor antagonists | ORTHO-MCNEIL PHARMACEUTICAL, INC. (US) | 2007-02-27 | — | — | US | disclosed |
| WO-2007019674-A1 | VIRAL POLYMERASE INHIBITORS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2007-02-22 | — | — | WO | disclosed |
| US-6858577-B1 | Indole peptidomimetics as thrombin receptor antagonists | ORTHO-MCNEIL PHARMACEUTICAL, INC. (US) | 2005-02-22 | — | — | US | disclosed |
| US-20030224999-A1 | Novel indole peptidomimetics as thrombin receptor antagonists | ZHANG HAN-CHENG (US) | 2003-12-04 | — | — | US | disclosed |
| EP-0925302-B1 | PALLADIUM CATALYZED INDOLIZATION | MERCK & CO INC (US) | 2002-11-20 | — | — | EP | disclosed |
| US-20020103138-A1 | Method for reducing or preventing the establishment, growth or metastasis of cancer by administering indole peptidomimetics PAR-1 antagonist and optionally PAR-2 antagonists | ORTHO-MCNEIL PHARMACEUTICAL CORPORATION | 2002-08-01 | — | — | US | disclosed |
| WO-2001000657-A2 | NOVEL INDOLE PEPTIDOMIMETICS AS THROMBIN RECEPTOR ANTAGONISTS | ORTHO-MCNEIL PHARMACEUTICAL, INC. (US) | 2001-01-04 | — | — | WO | disclosed |
| EP-0925302-A1 | PALLADIUM CATALYZED INDOLIZATION | Merck & Co., Inc. (US) | 1999-06-30 | — | — | EP | disclosed |
| US-5854268-A | Azetidine, pyrrolidine and piperidine derivatives | MERCK SHARP & DOHME, LTD. (GB) | 1998-12-29 | — | — | US | disclosed |
| US-5808064-A | HYDROSILATION OF AN INDOLE AS CHEMICAL INTERMEDIATE | MERCK & CO., INC. (US) | 1998-09-15 | — | — | US | disclosed |
| WO-1998006725-A1 | PALLADIUM CATALYZED INDOLIZATION | MERCK & CO., INC. (US) | 1998-02-19 | — | — | WO | disclosed |
| EP-0804434-A1 | AZETIDINE, PYRROLIDINE AND PIPERIDINE DERIVATIVES | MERCK SHARP & DOHME LTD. (GB) | 1997-11-05 | — | — | EP | disclosed |
| WO-1996004274-A1 | AZETIDINE, PYRROLIDINE AND PIPERIDINE DERIVATIVES | MERCK SHARP & DOHME LIMITED (GB) | 1996-02-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100168098-A1 | Viral Polymerase Inhibitors | POLR2A, POLR1E, POLR2E | AOC3 2706/4885BRD4 142/4885RAB9A 129/4885 |
| US-20080167476-A1 | Process for the preparation of 2-substituted-7-Boryl indoles and compounds | INMT, IDO2, IDO1 | AOC3 4070/4885BRD4 369/4885RAB9A 2216/4885 |
| US-20020103138-A1 | Method for reducing or preventing the establishment, growth or metastasis of cancer by administering indole peptidomimetics PAR-1 antagonist and optionally PAR-2 antagonists | F2RL1, F2R, IDO2 | AOC3 3198/4885BRD4 584/4885RAB9A 3270/4885 |
| US-20030224999-A1 | Novel indole peptidomimetics as thrombin receptor antagonists | PTAFR, F2R, F2RL1 | AOC3 3937/4885BRD4 1177/4885RAB9A 3640/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.